Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animal (1)
- Animals (1)
- Caco-2 Cells (1)
- Cancer (1)
- Colon carcinogenesis (1)
-
- Colorectal Neoplasms (1)
- Decision analysis (1)
- Disease Models (1)
- Disease Models, Animal (1)
- Gastrointestinal Hormones (1)
- Genotype (1)
- Guanylate Cyclase-Coupled (1)
- HEK293 Cells (1)
- Humans (1)
- Inbred BALB C (1)
- Inbred C57BL (1)
- Mice (1)
- Mice, Inbred BALB C (1)
- Mice, Inbred C57BL (1)
- Mice, Transgenic (1)
- Molecular genetics (1)
- Natriuretic Peptides (1)
- Obesity (1)
- Paracrine Communication (1)
- Peptide (1)
- Receptors (1)
- Receptors, Guanylate Cyclase-Coupled (1)
- Receptors, Peptide (1)
- Risk Factors (1)
- Signal Transduction (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
A Survey Of Physician Receptivity To Molecular Diagnostic Testing And Readiness To Act On Results For Early-Stage Colon Cancer Patients., Ronald E. Myers, Thomas Wolf, Phillip Shwae, Sarah E. Hegarty, Stephen C. Peiper, Scott A. Waldman
A Survey Of Physician Receptivity To Molecular Diagnostic Testing And Readiness To Act On Results For Early-Stage Colon Cancer Patients., Ronald E. Myers, Thomas Wolf, Phillip Shwae, Sarah E. Hegarty, Stephen C. Peiper, Scott A. Waldman
Department of Pharmacology and Experimental Therapeutics Faculty Papers
BACKGROUND: We sought to assess physician interest in molecular prognosic testing for patients with early stage colon cancer, and identify factors associated with the likelihood of test adoption.
METHODS: We identified physicians who care for patients with early-stage (pN0) colon cancer patients, mailed them a survey, and analyzed survey responses to assess clinician receptivity to the use of a new molecular test (GUCY2C) that identifies patients at risk for recurrence, and clinician readiness to act on abnormal test results.
RESULTS: Of 104 eligible potential respondents, 41 completed and returned the survey. Among responding physicians, 56 % were receptive to using …
Obesity-Induced Colorectal Cancer Is Driven By Caloric Silencing Of The Guanylin-Gucy2c Paracrine Signaling Axis., Jieru E. Lin, Francheska Colon-Gonzalez, Erik S. Blomain, Gilbert W. Kim, Amanda Aing, Brian Stoecker, Justin Rock, Adam E. Snook, Tingting Zhan, Terry M. Hyslop, Michal Tomczak, Richard S. Blumberg, Scott A. Waldman
Obesity-Induced Colorectal Cancer Is Driven By Caloric Silencing Of The Guanylin-Gucy2c Paracrine Signaling Axis., Jieru E. Lin, Francheska Colon-Gonzalez, Erik S. Blomain, Gilbert W. Kim, Amanda Aing, Brian Stoecker, Justin Rock, Adam E. Snook, Tingting Zhan, Terry M. Hyslop, Michal Tomczak, Richard S. Blumberg, Scott A. Waldman
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Obesity is a well-known risk factor for colorectal cancer but precisely how it influences risks of malignancy remains unclear. During colon cancer development in humans or animals, attenuation of the colonic cell surface receptor guanylyl cyclase C (GUCY2C) that occurs due to loss of its paracrine hormone ligand guanylin contributes universally to malignant progression. In this study, we explored a link between obesity and GUCY2C silencing in colorectal cancer. Using genetically engineered mice on different diets, we found that diet-induced obesity caused a loss of guanylin expression in the colon with subsequent GUCY2C silencing, epithelial dysfunction, and tumorigenesis. Mechanistic investigations …